Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production

Journal of Clinical Investigation

Volumn 115, Issue 6, 2005, Pages 1601-1606

  Bafica, Andre ^a,b   Scanga, Charles A ^a   Serhan, Charles ^c   Machado, Fabiana ^d   White, Sandy ^a   Sher, Alan ^a   Aliberti, Julio ^d,e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; GAMMA INTERFERON; ICOSANOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; LIPOXIN A; MESSENGER RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM DETECTION; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; HISTOPATHOLOGY; HOST RESISTANCE; IN VIVO STUDY; INFECTION RESISTANCE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SPLEEN CELL; TH1 CELL; WILD TYPE;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CYTOKINES; LIPOXINS; LUNG; MICE; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE SYNTHASE; SPLEEN; TH1 CELLS; TUBERCULOSIS, PULMONARY;

EID: 20444481328     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23949     Document Type: Article

References (30)

1. Cooper, A.M., et al. 1995. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology. 84:423-432.
2. Flynn, J.L., et al. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 2:561-572.
3. Flynn, J.L., et al. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515-2524.
4. de Jong, R., et al. 1998. Severe mycobacterial and Salmonella, infections in interleukin-12 receptor-deficient patients. Science. 280:1435-1438.
5. Altare, F., et al. 1998. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 280:1432-1435.
6. Jouanguy, E., et al. 1996. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335:1956-1961.
7. Keane, J., et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098-1104.
8. Jung, Y.J., Ryan, L., LaCourse, R., and North, R.J. 2003. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology. 109:295-299.
9. Roach. D.R., et al. 2001. Endogenous inhibition of antimycobacterial immunity by IL-10 varies between mycobacterial species. Scand. J. Immunol. 54:163-170.
10. Jung, Y.J., LaCourse, R., Ryan, L., and North, R.J. 2002. Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium tuberculosis lung infection in mice. Infect. Immun. 70:6436-6443.
11. Goldfeld, A.E. 2004. Genetic susceptibility to pulmonary tuberculosis in Cambodia. Tuberculosis (Edinb.). 84:76-81.
12. Aliberti, J. 2005. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat. Rev. Immunol. 5:162-170.
13. Aliberti, J., Hieny, S., Reis e Sousa, C., Serhan, C.N., and Sher, A. 2002. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:76-82.
14. Aliberti, J., Serhan, C., and Sher, A. 2002. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 196:1253-1262.
15. Scanga, C.A., et al. 2004. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect. Immun. 72:2400-2404.
16. MacMicking, J.D., et al. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 94:5243-5248.
17. Devchand, P.R., et al. 2005. A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. FASEB. J. 19:203-210.
18. Clish, C.B., et al. 1999. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:8247-8252.
19. Bannenberg, G., et al. 2004. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br. J. Pharmacol. 143:43-52.
20. Dai, G., and McMurray, D.N. 1999. Effects of modulating TGF-beta 1 on immune responses to mycobacterial infection in guinea pigs. Tuber. Lung Dis. 79:207-214.
21. Serhan, C.N. 2002. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution [review]. Prostaglandins Other Lipid Mediat. 68-69:433-455.
22. Ramstedt, U., Ng, J., Wigzell, H., Serhan, C.N., and Samuelsson, B. 1985. Action of novel eicosanoids lipoxin A and B on human natural killer cell cytocoxicity: effects on intracellular cAMP and target cell binding. J. Immunol. 135:3434-3438.
23. Hachicha, M., Pouliot, M., Petasis, N.A., and Serhan, C.N. 1999. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189:1923-1930.
24. Bandeira-Melo, C., et al. 2000. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J. Immunol. 164:2267-2271.
25. Canny, G., et al. 2002. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI)in human mucosal epithelia. Proc. Natl. Acad. Sci. U. S. A. 99:3902-3907.
26. Levy, O., Canny, G., Serhan, C.N., and Colgan, S.P. 2003. Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. Biochem. Soc. Trans. 31:795-800.
27. Bannenberg, G.L., Aliberti, J., Hong, S., Sher, A., and Serhan, C. 2004. Exogenous pathogen and plant 15-lipoxygenase initiate endogenous tipoxin A4 biosynthesis. J. Exp. Med. 199:515-523.
28. Israel, E., Cohn, J., Dube, L., and Drazen, J.M. 1996. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 275:931-936.
29. DuBuske, L.M., Grossman, J., Dube, L.M., Swanson, L.J., and Lancaster, J.F. 1997. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. Am. J. Manag. Care. 3:633-640.
30. Schwartz, H.J., Petty, T., Dube, L.M., Swanson, L.J., and Lancaster, J.F. 1998. A randomized controlled trial comparing ziteuton with cheophylline in moderate asthma. The Zileuton Study Group. Arch. Intern. Med. 158:141-148.